Juvenile Inflammatory Rheumatism (JIR) Cohorte
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Arthritis, Juvenile Rheumatoid. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Belgium, France, Germany, Morocco, Switzerland
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Setting up a Pediatric Cohort for Inflammatory Rheumatic Diseases
Overview
The investigators created a cohort of patients with juvenile inflammatory rheumatisms with the purpose to follow them prospectively, and investigate the tolerance and efficacy of immunosuppresive and biological agents.
Detailed description
The JIR-cohort has to be filled by an authorized investigator during or after the consultation. Each patient much be followed at least once a year.
Different data are requested in the JIR-cohort: diagnosis, treatment, adverse events and outcome.
Primary outcome measures
- Number of severe and very severe adverse event as a mesure of safety and tolerability [Time frame: 10 years]
- Number of treatments prescribed off label [Time frame: 10 Years]
- Length in months of drug survival in patient treated with at least two consecutive biological agents [Time frame: 10 Years]
Eligibility criteria
Inclusion criteria
- Patients with juvenile inflammatory diseases
- Age at onset up to 18 years old
- Consent according national codes of ethics and current laws
Exclusion criteria
- Non-consent from patients and/or legal representative
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
France · 25 centers
- CHU Belfort — Belfort
- CHRU Besançon — Besançon
- Hôpital Pellegrin enfants — Bordeaux
- CHRU Brest — Brest
- Hôpital Femme Mère Enfant — Bron
- CHU Clermont-Ferrand — Clermont-Ferrand
- CHU de Grenoble — Grenoble
- Hôpital Bicêtre — Le Kremlin-Bicêtre
- … and 17 more centers
Switzerland · 13 centers
- CHUV — Lausanne
- Kantonsspital Aarau — Aarau
- Kinderspital Basel — Basel
- Universitäts-Augenklinik Basel — Basel
- Ospedale Regionale di Bellinzona e valli — Bellinzona
- Kantonspital Graubunden — Chur
- Hôpital Ophtalmique — Lausanne
- Kinderspital Luzern — Lucerne
- … and 5 more centers
Belgium · 5 centers
- Hôpital Reine Fabiola — Brussels
- CHU Charleroi — Charleroi
- UZ Leuven — Leuven
- CHC Liège — Liège
- CHR Citadelle — Liège
Germany · 1 center
- University Hospital Muenster — Münster
Morocco · 1 center
- Hôpital Ibnou Rochd — Casablanca
Publications
- Pouletty M, Borocco C, Ouldali N, Caseris M, Basmaci R, Lachaume N, Bensaid P, Pichard S, Kouider H, Morelle G, Craiu I, Pondarre C, Deho A, Maroni A, Oualha M, Amoura Z, Haroche J, Chommeloux J, Bajolle F, Beyler C, Bonacorsi S, Carcelain G, Kone-Paut I, Bader-Meunier B, Faye A, Meinzer U, Galeotti C, Melki I. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimi PMID 32527868
Identifiers
NCT: NCT02377245 · JIR-001